Information Provided By:
Fly News Breaks for February 10, 2020
Feb 10, 2020 | 16:06 EDT
Stifel analyst Adam Walsh noted that the US Patent Trial and Appeal Board, or PTAB, released a final written decision in the inter partes review case between Corcept Therapeutics (CORT) and Neptune Generics, ruling in a "clear win" for Corcept that Neptune has not shown by a preponderance of the evidence that claims 1-7 of U.S. Patent No. 8,921,348 related to Korlym are unpatentable. Walsh said he still thinks that the PTAB PGR decision in November on the '214 patent, the Federal trial against Teva (TEVA) and the emerging pipeline are the main drivers of Corcept shares this year. He keeps a Hold rating on Corcept Therapeutics shares, which closed 3.5% higher at $14.04.
News For CORT;TEVA From the Last 2 Days
Nov 23, 2020 | 06:17 EST
Citi analyst Navann Ty recommends a pair trade of overweight Endo International (ENDP) and underweight Teva Pharmaceutical (TEVA). Endo shares trade at a discount versus the U.S. Speciality Pharma sector in general and Teva specifically, Ty tells investors in a research note. Further, Endo is less exposed to litigation risk than Teva, has higher operating margins, and similar leverage but a better liquidity profile, says the analyst. Ty keeps a Buy rating on Endo with a $7 price target and Neutral rating on Teva with a $10 price target.